Q4 2017 Earnings Forecast for Inogen, Inc (INGN) Issued By Leerink Swann
Inogen, Inc (NASDAQ:INGN) – Stock analysts at Leerink Swann decreased their Q4 2017 earnings estimates for shares of Inogen in a research report issued to clients and investors on Tuesday. Leerink Swann analyst D. Antalffy now anticipates that the medical technology company will earn $0.18 per share for the quarter, down from their previous estimate of $0.21. Leerink Swann currently has a “Outperform” rating and a $120.00 price target on the stock. Leerink Swann also issued estimates for Inogen’s Q2 2018 earnings at $0.44 EPS, Q3 2018 earnings at $0.42 EPS, Q4 2018 earnings at $0.30 EPS, FY2020 earnings at $1.98 EPS and FY2021 earnings at $2.39 EPS.
Other equities research analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target on the stock in a report on Thursday. Needham & Company LLC boosted their target price on shares of Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a research report on Wednesday. BidaskClub downgraded shares of Inogen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $90.00 target price on shares of Inogen in a research note on Tuesday, September 12th. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $103.14.
Shares of Inogen (INGN) opened at $114.19 on Thursday. Inogen has a fifty-two week low of $59.84 and a fifty-two week high of $124.90. The company has a market cap of $2,498.60, a P/E ratio of 97.33, a P/E/G ratio of 5.03 and a beta of 0.99.
Inogen (NASDAQ:INGN) last released its earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.04. The company had revenue of $69.00 million during the quarter, compared to the consensus estimate of $63.55 million. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The company’s revenue was up 26.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.25 EPS.
Several institutional investors and hedge funds have recently modified their holdings of the company. Schroder Investment Management Group purchased a new position in shares of Inogen during the 2nd quarter valued at about $132,000. Ameritas Investment Partners Inc. grew its position in shares of Inogen by 6.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after buying an additional 86 shares during the last quarter. Sei Investments Co. grew its position in shares of Inogen by 38.1% in the 2nd quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock worth $153,000 after buying an additional 443 shares during the last quarter. Victory Capital Management Inc. grew its position in shares of Inogen by 17.8% in the 2nd quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock worth $194,000 after buying an additional 307 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Inogen in the 1st quarter worth approximately $203,000.
In other news, Director Raymond Huggenberger sold 14,000 shares of the stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $91.67, for a total transaction of $1,283,380.00. Following the completion of the transaction, the director now owns 7,808 shares in the company, valued at approximately $715,759.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Matt Scribner sold 2,500 shares of the stock in a transaction on Friday, August 18th. The stock was sold at an average price of $92.45, for a total value of $231,125.00. Following the transaction, the executive vice president now owns 6,964 shares of the company’s stock, valued at approximately $643,821.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 67,000 shares of company stock valued at $6,424,010. Insiders own 5.31% of the company’s stock.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.